NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: LUPIN · data 2026-10-31
Lupin Limited
In plain words
Price: 20.5% below its 52-week high of ₹2,529.5.
Delivery: 56.8% of traded shares were kept for delivery over the last 10 sessions, against 58.5% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹29,967 cr |
| Net profit (last 12 months) | ₹5,529 cr |
| Sales growth, 3 years (yearly) | 18.8% |
| Profit growth, 3 years (yearly) | 131.5% |
At a glance
Promoters 46.8% (-0.1 pts in a year), pledged 0.0%, institutions 47.1%.
P/E 16.7, dividend yield 0.9%. Price relative to earnings and book value (low is cheaper, not better).
ROE 26.9%, ROCE 30.7%, operating margin 25.2%: how much profit it earns on the money it uses.
Debt/equity 0.30, Profit growth 131.5% and sales growth 18.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (26.9%).
- Healthy operating margin (25.2%).
- Profit grew 131.5% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
18/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 58.7% over the last 20 sessions vs 58.0% in the 40 before (1.01x); shares delivered per day 0.77x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 35 schemes hold it, about ₹4,554 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: Verdict "None", sustained score 18/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 6 Aug 26Results Results board meeting -1.0% next session
- 17 Jul 26Dividend Dividend ₹18 (ex-date) -0.9% next session
- 7 May 26Results Results board meeting -2.6% next session
- 12 Feb 26Results Results board meeting -0.4% next session
- 6 Nov 25Results Results board meeting -1.3% next session
- 5 Aug 25Results Results board meeting -1.6% next session
- 25 Jul 25Dividend Dividend ₹12 (ex-date) +1.0% next session
- 14 May 25Results Results board meeting +0.4% next session
- 11 Feb 25Results Results board meeting -6.6% next session
- 7 Nov 24Results Results board meeting -2.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 46.84% | 46.85% | 46.86% | 46.89% |
| Foreign institutions (FII) | 23.28% | 22.42% | 21.71% | 21.49% |
| Domestic institutions (DII) | 23.78% | 24.65% | 25.32% | 25.58% |
| Mutual funds | 14.58% | 14.84% | 16.93% | 18.01% |
| Retail investors | 4.99% | 4.92% | 4.92% | 4.96% |
| Number of shareholders | 2,97,301 | 3,00,283 | 2,90,411 | 2,88,931 |
Common questions
How much do promoters hold in Lupin Limited?
Promoters held 46.84% of Lupin Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Lupin Limited debt-free?
Its latest reported debt-to-equity ratio is 0.3.
What is Lupin Limited's P/E ratio?
About 16.7, based on the last 12 months' earnings and a price of ₹2,011 (data 2026-10-31).
What is the 52-week high and low of Lupin Limited?
The 52-week high is ₹2,529.5 and the 52-week low is ₹1,892.9.
Mutual funds holding Lupin Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 35 schemes holding about ₹4,554 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Large & Midcap Fund | Mirae Asset Mutual Fund | 1.87% | ₹801 cr |
| Mirae Asset Midcap Fund | Mirae Asset Mutual Fund | 3.34% | ₹653 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 6.17% | ₹566 cr |
| Nippon India Growth Mid Cap Fund | Nippon India Mutual Fund | 0.89% | ₹447 cr |
| SBI Midcap Fund | SBI Mutual Fund | 1.83% | ₹426 cr |
| NIPPON INDIA LARGE CAP FUND | Nippon India Mutual Fund | 0.78% | ₹400 cr |
| Nippon India Multi Cap Fund | Nippon India Mutual Fund | 0.72% | ₹387 cr |
| SBI Large and Midcap Fund | SBI Mutual Fund | 0.52% | ₹211 cr |
| Mirae Asset Multicap Fund | Mirae Asset Mutual Fund | 1.79% | ₹96 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 5.00% | ₹87 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.27% | ₹79 cr |
| Nippon India Flexi Cap Fund | Nippon India Mutual Fund | 0.72% | ₹66 cr |
| Mirae Asset Flexi Cap Fund | Mirae Asset Mutual Fund | 1.43% | ₹63 cr |
| Nippon India Aggressive Hybrid Fund | Nippon India Mutual Fund | 1.24% | ₹48 cr |
| Nippon India ETF Nifty Midcap 150 | Nippon India Mutual Fund | 1.22% | ₹47 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Lupin Limited | ₹2,011 | ₹91,870 cr | 16.7 | — | 26.9% | 30.7% | 0.3 | +2.8% |
| Cipla Ltd | ₹1,378.9 | ₹1,11,486 cr | 38.5 | 3.2 | 11.8% | 14.5% | 0.02 | -13.1% |
| Aurobindo Pharma Ltd | ₹1,681.4 | ₹96,537 cr | 26.3 | — | 9.9% | 15.1% | 0.21 | +51.1% |
| Granules India Limited | ₹839.75 | ₹20,804 cr | 31.2 | — | 13.5% | 17.9% | 0.3 | +46.8% |
| Sudeep Pharma Limited | ₹1,068.3 | ₹12,048 cr | 64.1 | 12.6 | 25.1% | 28.4% | 0.17 | +46.3% |
| Amrutanjan Health Care Limited | ₹496.65 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -33.0% |
Compare LUPIN with CIPLA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LUPIN in NSE Scanner →